The Circulating Cell-Free Tumor DNA Market is estimated to be valued at US$ 6.1 billion in 2023 and is expected to exhibit a CAGR of 22.9% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.Market Overview:Circulating cell-free tumor DNA (ctDNA) refers to the DNA fragments released into the bloodstream by cancerous tumors. This market...
Liquid biopsy is an emerging non-invasive method for detecting cancer by analyzing a blood sample. By detecting traces of cancer biomarkers in the blood, liquid biopsy may provide insights into tumor genetics, evolution, and response to therapies. Some key aspects of liquid biopsy are discussed below.How Liquid Biopsy WorksLiquid Biopsy works by detecting various types of biomarkers that tumors...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian